The choice of data when starting an RWE study is critical. Each option—whether administrative claims, electronic medical records, registries, or surveys—offers unique strengths and limitations. Selecting the right one depends on your research objectives and the nuances of the healthcare system where the data originates.

The European Health Technology Assessment (EU-HTA) aims to harmonise HTA across Europe, enhancing efficiency and reducing duplication of work for national authorities. This paper explores key components of the EU-HTA framework, challenges, future perspectives, and implications for pharmaceutical companies, primarily concentrating on drug evaluation over medical devices